The FDA has partially halted enrollment in Biohaven's epilepsy trials over a safety finding in animal studies, adding to a string of setbacks for the drug.
Endpoints News
@endpts
The biopharma world is here. Get the industry’s most comprehensive daily news reports at endpts.com/subscribe
